-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-04-28
Values as of: 2024-04-28
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Company Website : www.spdrs.com
Currency: USD
Country : USA
Inception Date: 19/06/2006
Primary Benchmark: S&P Pharms Select Industry TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.35%
Management Expense Ratio: 0.35 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| CRTTF | Cortus Metals Inc | 4.39 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
-0.28 (-0.19%) |
USD 40.26B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
-0.13 (-0.18%) |
USD 2.86B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
+0.33 (+0.31%) |
USD 1.18B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
+0.24 (+0.27%) |
USD 0.21B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
+0.08 (+0.32%) |
USD 0.14B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
-0.53 (-1.37%) |
USD 0.12B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
-1.28 (-1.35%) |
USD 0.08B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
+0.12 (+0.43%) |
USD 0.05B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
-0.56 (-0.87%) |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
-0.55 (-1.87%) |
USD 0.01B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| INAV | 10.31 % | 0.00 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -5.05% | 29% | F | 23% | F | ||
| Dividend Return | 0.42% | 92% | A | 24% | F | ||
| Total Return | -4.63% | 29% | F | 22% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -6.06% | 19% | F | 23% | F | ||
| Dividend Return | 1.40% | 83% | B | 18% | F | ||
| Total Return | -4.66% | 24% | F | 20% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -0.75% | 21% | F | 46% | F | ||
| Dividend Return | 3.89% | 61% | D- | 12% | F | ||
| Total Return | 3.13% | 21% | F | 34% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 1.92% | 14% | F | 48% | F | ||
| Dividend Return | 2.53% | 19% | F | 40% | F | ||
| Total Return | 0.61% | 68% | D+ | 15% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 15.67% | 62% | D | 67% | D+ | ||
| Risk Adjusted Return | 16.15% | 24% | F | 39% | F | ||
| Market Capitalization | 0.50B | 33% | F | 33% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
